期刊： EXPERT OPINION ON EMERGING DRUGS, 2021; 26 (1)
Introduction Hepatocellular carcinoma (HCC) is a major challenge in oncology. It ranks fourth in most common causes of cancer death worldwide. Despite......
期刊： EXPERT OPINION ON EMERGING DRUGS, 2021; 26 (1)
Introduction The large percentage of adults with major depressive disorder (MDD) insufficiently responding and/or tolerating conventional monoamine-ba......
期刊： EXPERT OPINION ON EMERGING DRUGS, 2022; 27 (2)
Introduction: Functional cure, defined as sustained HBsAg seroclearance, is associated with favorable outcomes in chronic hepatitis B (CHB). While nuc......
期刊： EXPERT OPINION ON EMERGING DRUGS, 2022; 27 (4)
IntroductionBoth vaccines and antiviral drugs represent the mainstay for preventing and treating influenza. However, approved M2 ion channel inhibitor......
期刊： EXPERT OPINION ON EMERGING DRUGS, 2022; 27 (2)
Introduction: Epidermal growth factor receptor (EGFR) is one of the most common driver gene mutations in non-small-cell lung cancer (NSCLC). EGFR-tyro......
期刊： EXPERT OPINION ON EMERGING DRUGS, 2017; 22 (2)
Introduction: Acute and chronic graft rejection continues to be an important problem after solid organ transplantation. With the introduction of poten......
